Article
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology (Baltimore, Md.) - 1 Aug 2017
Poordad Fred, Felizarta Franco, Asatryan Armen, Sulkowski Mark S, Reindollar Robert W, Landis Charles S, Gordon Stuart C, Flamm Steven L, Fried Michael W, Bernstein David E, Lin Chih-Wei, Liu Ran, Lovell Sandra S, Ng Teresa I, Kort Jens, Mensa Federico J
Abstract excerpt
Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment. Treatment options for patients who failed previous DAA-containing regimens, particularly those with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.